A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma

Trial Profile

A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Avadomide (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Mar 2017 Status changed from recruiting to discontinued.
    • 20 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
    • 18 Aug 2015 Planned number of patients changed from 45 to 40 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top